NCT03269344View on ClinicalTrials.gov

Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

June 5, 2017

Primary Completion Date

December 9, 2020

Study Completion Date

December 9, 2020

Conditions
Oropharynx Cancer
Interventions
DRUG

Gabapentin

Gabapentin is an anticonvulsant and has been used to manage neuropathic pain and is FDA-approved for the treatment of post-herpetic neuralgia and partial onset seizures

DRUG

Placebo Oral Capsule

Placebo

Trial Locations (1)

48202

Henry Ford Hospital, Detroit

All Listed Sponsors
lead

Henry Ford Health System

OTHER

NCT03269344 - Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer | Biotech Hunter | Biotech Hunter